Vicarious Surgical (RBOT) Expected to Announce Quarterly Earnings on Thursday

Vicarious Surgical (NYSE:RBOT) is expected to be posting its Q2 2026 resultson Thursday, July 30th. Analysts expect the company to announce earnings of ($1.15) per share for the quarter. Parties can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:30 PM ET.

Vicarious Surgical Price Performance

NYSE RBOT opened at $0.10 on Wednesday. The stock has a market capitalization of $712,400.00, a PE ratio of -0.01 and a beta of 1.88. Vicarious Surgical has a 1 year low of $0.10 and a 1 year high of $10.50. The business’s 50-day moving average is $0.38 and its 200 day moving average is $1.01.

Institutional Investors Weigh In On Vicarious Surgical

Several institutional investors and hedge funds have recently bought and sold shares of the business. Armistice Capital LLC purchased a new position in shares of Vicarious Surgical during the fourth quarter valued at approximately $1,314,000. Jane Street Group LLC purchased a new stake in Vicarious Surgical in the fourth quarter worth $98,000. Connective Capital Management LLC purchased a new stake in Vicarious Surgical in the third quarter worth $169,000. Dimensional Fund Advisors LP lifted its stake in Vicarious Surgical by 22.1% in the third quarter. Dimensional Fund Advisors LP now owns 19,975 shares of the company’s stock worth $110,000 after acquiring an additional 3,615 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Vicarious Surgical by 26.0% in the fourth quarter. Geode Capital Management LLC now owns 40,494 shares of the company’s stock valued at $88,000 after acquiring an additional 8,344 shares in the last quarter. Hedge funds and other institutional investors own 47.27% of the company’s stock.

Vicarious Surgical Company Profile

Vicarious Surgical develops a next-generation robotic surgical system that integrates virtual reality (VR) with minimally invasive instrumentation. Its flagship offering combines ultra-slender, articulated robotic arms with a VR surgeon console, allowing physicians to perform laparoscopic procedures with enhanced precision, dexterity and visual immersion. The platform is designed to reduce patient trauma compared with traditional open or laparoscopic surgery and to expand surgeon access to challenging operative sites.

The company’s technology is intended for use across multiple surgical specialties, including general surgery, gynecology and urology.